A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect on Urine Albumin-to-Creatinine Ratio (UACR), Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of Multiple Oral Doses of MT-3995 as Add-on Therapy to ACE-I or ARB in Type II Diabetic Nephropathy Subjects with Albuminuria and an eGFR ≥30-<60 mL/min/1.73m2.

Trial Profile

A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect on Urine Albumin-to-Creatinine Ratio (UACR), Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of Multiple Oral Doses of MT-3995 as Add-on Therapy to ACE-I or ARB in Type II Diabetic Nephropathy Subjects with Albuminuria and an eGFR ≥30-<60 mL/min/1.73m2.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Feb 2015

At a glance

  • Drugs MT 3995 (Primary)
  • Indications Diabetic nephropathies; Proteinuria
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Mitsubishi Tanabe Pharma Corporation
  • Most Recent Events

    • 08 Feb 2015 Status changed from active, no longer recruiting to completed ClinicalTrials.gov.
    • 25 Sep 2014 Planned End Date changed from 1 Dec 2013 to 1 Jan 2015 as reported by ClinicalTrials.gov record.
    • 25 Sep 2014 Planned primary completion date changed from 1 Dec 2013 to 1 Jan 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top